Arcus Biosciences, Inc. (RCUS) Reports Break-Even Earnings for Q2Zacks Investment Research • 08/06/25
Arcus Biosciences Reports Second-Quarter 2025 Financial Results and Provides a Pipeline UpdateBusiness Wire • 08/06/25
Arcus Biosciences' Quemliclustat Receives Orphan Drug Designation for Pancreatic CancerBusiness Wire • 07/10/25
Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed ResponseBusiness Wire • 06/01/25
Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/06/25
Arcus Biosciences Reports First-Quarter 2025 Financial Results and Provides a Pipeline UpdateBusiness Wire • 05/06/25
Arcus Biosciences to Present First Combination Data for HIF-2a Inhibitor Casdatifan Plus Cabozantinib in an Oral Presentation at the 2025 ASCO Annual MeetingBusiness Wire • 04/23/25
Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2025 Financial Results and Pipeline UpdateBusiness Wire • 04/22/25
Arcus Biosciences: A High-Risk Speculation With Multiple Large, Near-Term CatalystsSeeking Alpha • 04/02/25
Arcus Biosciences, Inc. (RCUS) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 02/26/25
Arcus Biosciences Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides a Pipeline UpdateBusiness Wire • 02/25/25
Arcus Biosciences Retains Rights to Casdatifan, a Potential Best-in-Class HIF-2a Inhibitor, and Announces Pricing of $150 Million Common Stock OfferingBusiness Wire • 02/18/25
New Data Demonstrated Best-in-Class Potential for Casdatifan, a HIF-2a Inhibitor, in Patients with Metastatic Kidney CancerBusiness Wire • 02/15/25
Arcus Biosciences to Present New Data from Casdatifan, a HIF-2a Inhibitor, in an Oral Presentation at the 2025 ASCO GU SymposiumBusiness Wire • 02/10/25
Arcus Biosciences Appoints Richard Markus, M.D., Ph.D. as Chief Medical OfficerBusiness Wire • 01/21/25
Arcus Biosciences to Participate in the 43rd Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 12/19/24
Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/06/24
Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline UpdateBusiness Wire • 11/06/24